Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2025-04-07 Transaction in Own Shar…
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is titled 'Disclosure of trading in own shares' and contains detailed tables listing daily volumes, prices, brokers, and transaction times for the company's repurchase of its own shares. It references applicable laws on share repurchases and provides granular transaction data. This matches the definition of a 'Transaction in Own Shares' filing, which reports the company's buyback or sale of its own shares. The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. There is no indication that this is a regulatory announcement, certification, or other report type. Therefore, the correct classification is POS (Transaction in Own Shares).
2025-04-07 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is titled 'Déclaration des transactions sur actions propres' which translates to 'Declaration of transactions on own shares'. It details daily aggregated and individual transactions of Sanofi's own shares, including volumes, prices, dates, and market codes. The content is a detailed report of the company's buyback or sale of its own shares, consistent with regulatory requirements for disclosure of such transactions. There is no indication of financial results, management commentary, or other report types. The document is not an announcement of a report but the actual declaration of transactions. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length is substantial (15,000 characters), supporting that it is a full declaration rather than a brief announcement.
2025-04-07 French
6-K
Regulatory Filings
2025-04-04 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions - FEVRIER 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations relatives au nombre total de droits de vote et d'actions" (Information relating to the total number of voting rights and shares) and explicitly references French regulations (Article L. 233-8 II du Code de commerce and Article 223-16 du Règlement général de l'Autorité des Marchés Financiers). It provides a table detailing the number of shares and voting rights as of a specific date (February 28, 2025). This type of mandatory disclosure regarding the total number of shares and voting rights is a specific regulatory filing in France, often related to capital structure changes or mandatory periodic updates. While it touches upon capital structure, it is primarily a disclosure of voting rights. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the closest fit as it relates to the capital structure components (shares and voting rights), although 'RNS' (Regulatory Filings) is a strong fallback. Given the specific nature of reporting total voting rights as mandated by financial authorities, 'SHA' is selected as the most specific category related to the composition of the share capital and voting rights, which is a key component of capital structure reporting.
2025-04-03 French
Sanofi: Information concerning the total number of voting rights and shares - February 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it concerns 'Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce... and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers'. It provides a table detailing the total number of issued shares and the number of voting rights as of a specific date (February 28, 2025). This type of mandatory disclosure regarding share structure and voting power aligns directly with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), as it reports on the current state of voting rights, even if it's not the final result of a specific vote, it is a regulatory filing concerning voting rights structure.
2025-04-03 English
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Regulatory Filings Classification · 95% confidence The document is explicitly titled and formatted as a "Press Release". It announces specific corporate news: the FDA granting orphan drug designation to a drug candidate (rilzabrutinib) for two rare diseases. This type of announcement, focusing on clinical/regulatory milestones and key business updates, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a formal press release announcing a significant regulatory event (Orphan Drug Designation) and includes quotes from management and contact information, it aligns best with the function of an Earnings Release (ER) which often includes key operational and regulatory highlights, or potentially RNS if it were a less comprehensive regulatory update. Given the structure and content (major news announcement, management quotes, forward-looking statements), ER is a strong candidate, but since it is not explicitly reporting quarterly financial results (which would favor ER), and it is a general announcement of a regulatory event, RNS (Regulatory Filings - the fallback for miscellaneous regulatory announcements) is also plausible. However, in many databases, major press releases announcing significant regulatory milestones that are not tied to a quarterly report are often categorized under the most specific relevant category if available, or RNS. Since the content is a major, time-sensitive announcement about regulatory status, and it is not a full financial report (10-K, IR) or a presentation (IP), RNS is the most appropriate general regulatory category for non-standard filings. Given the context of a press release announcing a regulatory event, RNS is the safest classification if ER is reserved strictly for financial performance summaries. I will classify it as RNS as it is a general regulatory announcement/press release not fitting other specific categories like DIV, CAP, or ER (which usually focuses on financial performance numbers).
2025-04-03 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.